Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 123 results

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

W

Murphy SJ, Wang L, Anderson LA, Steinlauf A, Present DH, Mechanick JI. 2009. Withdrawal of corticosteroids in inflammatory bowel disease patients after dependency periods ranging from 2 to 45 years: a proposed method.. Aliment Pharmacol Ther. 30(10):1078-86.

V

Gordon BL, Galati J, Yang S, Katz PO, Scherl EJ. 2020. Vitamin C Deficiency: An Under-Recognized Condition in Crohn's Disease.. ACG Case Rep J. 7(7):e00424.

Battat R, Kopylov U, Szilagyi A, Saxena A, Rosenblatt DS, Warner M, Bessissow T, Seidman E, Bitton A. 2014. Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management.. Inflamm Bowel Dis. 20(6):1120-8.

Battat R, Kopylov U, Byer J, Sewitch MJ, Rahme E, Nedjar H, Zelikovic E, Dionne S, Bessissow T, Afif W et al.. 2017. Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational pilot study.. Eur J Gastroenterol Hepatol. 29(12):1361-1367.

Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L et al.. 2018. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.. Am J Gastroenterol. 113(9):1345.

Hirten R, Longman RS, Bosworth BP, Steinlauf A, Scherl E. 2015. Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.. Am J Gastroenterol. 110(12):1737-8.

Choi AJ, Atteberry P, Lukin DJ. 2019. Vaccination in the Elderly and IBD.. Curr Treat Options Gastroenterol. 17(4):492-505.

U

Malik F, Scherl E, Weber U, Carrino JA, Epsten M, Wichuk S, Pedersen SJ, Paschke J, Schwartzman S, Kroeber G et al.. 2021. Utility of magnetic resonance imaging in Crohn's associated sacroiliitis: A cross-sectional study.. Int J Rheum Dis.

Panaccione R, Danese S, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT et al.. 2020. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.. Aliment Pharmacol Ther. 52(11-12):1658-1675.

Qazi T, Verma R, Hamilton MJ, Kaplan ER, Redline S, Burakoff R. 2019. The Use of Actigraphy Differentiates Sleep Disturbances in Active and Inactive Crohn's Disease.. Inflamm Bowel Dis. 25(6):1044-1053.

Gold SL, Magro C, Scherl E. 2018. A Unique Infusion Reaction to Vedolizumab in a Patient With Crohn's Disease.. Gastroenterology. 155(4):981-982.

Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. 2015. Ulcerative Colitis Care Pathway.. Gastroenterology. 149(1):238-45.

T

Braun D, Longman RS, Albert ML. 2005. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation.. Blood. 106(7):2375-81.

Kiuru M, Camp B, Adhami K, Jacob V, Magro C, Wildman H. 2015. Treatment of metastatic cutaneous Crohn disease with certolizumab.. Dermatol Online J. 21(11)

Lima S, Gogokhia L, Viladomiu M, Chou L, Putzel G, Jin W, Pires S, Guo C-J, Gerardin Y, Crawford CV et al.. 2021. Transferable Immunoglobulin A-Coated Odoribacter splanchnicus in Responders to Fecal Microbiota Transplantation for Ulcerative Colitis Limits Colonic Inflammation.. Gastroenterology.

Zegarra-Ruiz DF, Kim DV, Norwood K, Kim M, Wu W-JH, Saldana-Morales FB, Hill AA, Majumdar S, Orozco S, Bell R et al.. 2021. Thymic development of gut-microbiota-specific T cells.. Nature. 594(7863):413-417.

Cohen-Mekelburg S, Tafesh Z, Coburn E, Weg R, Malik N, Webb C, Hammad H, Scherl E, Bosworth BP. 2018. Testing and Treating Small Intestinal Bacterial Overgrowth Reduces Symptoms in Patients with Inflammatory Bowel Disease.. Dig Dis Sci. 63(9):2439-2444.

Patel A, Namn Y, Shah SL, Scherl E, Wan DW. 2019. Takotsubo cardiomyopathy after an upper and lower endoscopy: a case report and review of the literature.. J Med Case Rep. 13(1):81.

S

Sedano R, Hogan M, Nguyen TM, Chang J, Zou GY, Macdonald JK, Casteele NVande, Hanzel J, Crowley E, Battat R et al.. 2021. Systematic review and Meta-analysis: Clinical, Endoscopic, Histologic and Safety Placebo Rates in Induction and Maintenance trials of Ulcerative Colitis.. J Crohns Colitis.

Koczka CPhilip, Abramowitz M, Goodman AJ. 2012. The study of bone demineralization and its risk factors in an Afro-Caribbean subset of patients with inflammatory bowel disease.. Eur J Gastroenterol Hepatol. 24(7):759-61.

Jacob V, Crawford C, Cohen-Mekelburg S, Viladomiu M, Putzel GG, Schneider Y, Chabouni F, OʼNeil S, Bosworth B, Woo V et al.. 2017. Single Delivery of High-Diversity Fecal Microbiota Preparation by Colonoscopy Is Safe and Effective in Increasing Microbial Diversity in Active Ulcerative Colitis.. Inflamm Bowel Dis. 23(6):903-911.

Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS et al.. 2019. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis.. Clin Gastroenterol Hepatol. 17(12):2497-2505.e1.

Zhang S, Dogan B, Guo C, Herlekar D, Stewart K, Scherl EJ, Simpson KW. 2020. Short Chain Fatty Acids Modulate the Growth and Virulence of Pathosymbiont and Host Response.. Antibiotics (Basel). 9(8)

Battat R, Duijvestein M, Casteele NVande, Singh S, Dulai PS, Valasek MA, Mimms L, McFarland J, Hester KD, Renshaw M et al.. 2018. Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease.. Clin Gastroenterol Hepatol.

Kumar A, Magro C, Lukin DJ. 2020. Scattered Skin Eruptions in a Patient With Inflammatory Bowel Disease.. Gastroenterology.